Edwards Lifesciences Co. (NYSE:EW) Stock Holdings Trimmed by Matrix Private Capital Group LLC

Matrix Private Capital Group LLC decreased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 8.5% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,901 shares of the medical research company’s stock after selling 363 shares during the quarter. Matrix Private Capital Group LLC’s holdings in Edwards Lifesciences were worth $323,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of EW. Core Alternative Capital raised its stake in shares of Edwards Lifesciences by 96.1% in the 1st quarter. Core Alternative Capital now owns 353 shares of the medical research company’s stock worth $29,000 after buying an additional 173 shares in the last quarter. Jones Financial Companies Lllp acquired a new position in Edwards Lifesciences during the first quarter worth about $33,000. MCF Advisors LLC lifted its holdings in Edwards Lifesciences by 179.6% in the 1st quarter. MCF Advisors LLC now owns 411 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 264 shares during the last quarter. Compass Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $31,000. Finally, CoreCap Advisors LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $44,000. 79.25% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $74.07 on Friday. Edwards Lifesciences Co. has a one year low of $67.13 and a one year high of $98.35. The business’s 50-day moving average price is $83.10 and its two-hundred day moving average price is $84.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.15 and a quick ratio of 2.30. The company has a market capitalization of $45.03 billion, a P/E ratio of 32.77, a price-to-earnings-growth ratio of 4.11 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. The firm had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.51 billion. Edwards Lifesciences had a return on equity of 25.43% and a net margin of 24.56%. The firm’s revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.63 earnings per share. Analysts anticipate that Edwards Lifesciences Co. will post 2.55 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction on Wednesday, July 5th. The shares were sold at an average price of $90.78, for a total transaction of $2,664,393.00. Following the transaction, the director now directly owns 54,252 shares of the company’s stock, valued at $4,924,996.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, VP Catherine M. Szyman sold 5,000 shares of the business’s stock in a transaction on Tuesday, June 13th. The shares were sold at an average price of $85.81, for a total value of $429,050.00. Following the completion of the sale, the vice president now directly owns 35,056 shares in the company, valued at $3,008,155.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael A. Mussallem sold 29,350 shares of the company’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $90.78, for a total transaction of $2,664,393.00. Following the sale, the director now directly owns 54,252 shares of the company’s stock, valued at $4,924,996.56. The disclosure for this sale can be found here. In the last 90 days, insiders sold 174,859 shares of company stock valued at $14,541,940. Insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the subject of a number of research reports. Royal Bank of Canada restated an “outperform” rating and set a $96.00 target price on shares of Edwards Lifesciences in a report on Thursday, August 17th. Mizuho upped their target price on Edwards Lifesciences from $95.00 to $102.00 in a report on Monday, July 17th. Truist Financial lifted their price target on Edwards Lifesciences from $101.00 to $105.00 in a research note on Wednesday, July 19th. TheStreet lowered shares of Edwards Lifesciences from a “b-” rating to a “c+” rating in a research note on Wednesday, August 9th. Finally, StockNews.com initiated coverage on shares of Edwards Lifesciences in a research report on Thursday, August 17th. They issued a “buy” rating on the stock. One analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $92.42.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.